Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Portfolio Pulse from Avi Kapoor
Jim Cramer shared his views on several stocks on CNBC's 'Mad Money Lightning Round,' recommending selling Petrobras (PBR) and buying Enterprise Products Partners (EPD), Cheniere Energy (LNG), Recursion Pharmaceuticals (RXRX), Casey's General Stores (CASY), and Broadcom (AVGO). Analysts have recently updated their price targets for EPD, CASY, and RXRX, while critics have raised concerns about Broadcom's cloud licensing practices.
April 24, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jim Cramer recommends selling Petrobras (PBR), with a slight price increase observed.
Cramer's negative stance, despite a small price rise, suggests skepticism about PBR's future performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cramer recommends buying Broadcom (AVGO), amid criticisms of its cloud licensing practices and a significant price gain.
Cramer's buy recommendation, coupled with a notable price increase, suggests confidence in AVGO's resilience against criticisms.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Cramer calls Casey's General Stores (CASY) a 'winner,' with a slight price decrease and a minor price target adjustment by analysts.
Despite a small price drop and a slight price target reduction, Cramer's endorsement suggests optimism for CASY's future.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 85
POSITIVE IMPACT
Cramer recommends buying EPD, supported by positive analyst ratings and a slight price decline.
Cramer's endorsement and analyst upgrades, despite a minor price drop, indicate strong future potential for EPD.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Cramer labels Cheniere Energy (LNG) as 'terrific,' despite a 1% price drop.
Cramer's positive outlook on LNG, even with a recent price decrease, suggests confidence in its long-term value.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Cramer sees Recursion Pharmaceuticals (RXRX) as a 'real winner,' with a recent leadership appointment and price increase.
Cramer's recommendation and the appointment of a new chief R&D officer, alongside a price increase, highlight RXRX's growth potential.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90